BIIB Stock: Price, Forecast, Financials & AI Analysis

Loading chart...

High

195.200

Open

189.680

VWAP

192.72

Vol

931.58K

Mkt Cap

28.56B

Low

189.500

Amount

179.53M

EV/EBITDA(TTM)

8.88

Total Shares

147.64M

30.57B

EV/OCF(TTM)

11.80

P/S(TTM)

2.87

Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).

Events Timeline

(ET)

2026-05-08

05:20:00

Eisai and Biogen FDA Review Period Extended to August 24

2026-05-07 (ET)

2026-05-07

17:30:00

Remitly Global to Replace Apellis Pharmaceuticals

News

9.0

05-08Newsfilter

PinnedFDA Extends LEQEMBI Review Period by Three Months

9.0

05-08Yahoo Finance

Biogen and Eisai FDA Review Extended

9.0

05-08NASDAQ.COM

FDA Extends LEQEMBI Review Period

9.0

05-08seekingalpha

FDA Extends Review Period for Leqembi IQLIK Injection

9.0

05-08PRnewswire

FDA Extends LEQEMBI Review Period by Three Months

9.5

04-30CNBC

Eli Lilly Reports Strong Q1 Performance with Revenue Surge

26 Analyst Rating

Wall Street analysts forecast BIIB stock price to rise

11 Buy

14 Hold

1 Sell

Moderate Buy

Current: 0.000

Low

143.00

Averages

204.45

High

246.00

Current: 0.000

Low

143.00

Averages

204.45

High

246.00

Freedom Broker

Ilya Zubkov

Hold

Buy

upgrade

$185 -> $245

AI Analysis

2026-05-01

Reason

Freedom Broker

Ilya Zubkov

Price Target

$185 -> $245

AI Analysis

2026-05-01

upgrade

Hold

Buy

Reason

Freedom Broker analyst Ilya Zubkov upgraded Biogen (BIIB) to Buy from Hold with a price target of $245, up from $185. The firm views the company's acquisition of Apellis (APLS) as "strategically sound" and a "necessary step given the expected revenue headwinds from an aging product portfolio." The deal should support Biogen's near-term results and partially reverse its anticipated revenue decline trajectory, the analyst tells investors in a research note. Freedom sees the acquisition as reshaping Biogen's growth narrative.

Truist

Hold

maintain

$189 -> $190

2026-05-01

Reason

Truist

Price Target

$189 -> $190

2026-05-01

maintain

Hold

Reason

Truist raised the firm's price target on Biogen to $190 from $189 and keeps a Hold rating on the shares. The firm has updated its model after the company's Q1 results, also maintaining its concerns regarding Biogen's forward revenue growth trajectory, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for BIIB

Unlock Now

Valuation Metrics

The current forward P/E ratio for Biogen Inc (BIIB.O) is 13.55, compared to its 5-year average forward P/E of 13.90. For a more detailed relative valuation and DCF analysis to assess Biogen Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

13.90

Current PE

13.55

Overvalued PE

17.41

Undervalued PE

10.39

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

10.38

Current EV/EBITDA

9.94

Overvalued EV/EBITDA

12.76

Undervalued EV/EBITDA

8.01

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.34

Current PS

2.74

Overvalued PS

4.16

Undervalued PS

2.53

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

Top stocks for one week gain

Intellectia · 13 candidates

Region: USPrice: >= $-100.00Volume: >= -100Price Change Pct: >= $0.00Relative Vol: >= 1.50Moving Average Relationship: PriceAboveMA5, PriceAboveMA20, PriceAboveMA60, PriceCrossAboveMA20Week Price Change Pct: >= $0.00Is Index Component: GSPC, NDX, RUTEma 5: >= -100Ema 20: >= -100Ema 60: >= -100One Day Predict Return: >= 0.0%One Week Rise Prob: >= 50One Week Predict Return: >= 0.0%Monthly Average Dollar Volume: >= -100Macd: bullish

Ticker

Name

Market Cap$

LXFR

Luxfer Holdings PLC

380.94M

KFRC

Kforce Inc

851.60M

VRNS

Varonis Systems Inc

3.13B

KALV

Kalvista Pharmaceuticals Inc

1.37B

BIIB

Biogen Inc

28.70B

LAW

CS Disco Inc

284.98M

Technical Analysis on vaccine

Intellectia · 6 candidates

Market Cap: >= 2.00BSector: Healthcare, Healthcare Services & Equipment, Pharmaceuticals & Medical ResearchThemes: BiotechRsi Category: moderateMoving Average Relationship: PriceAboveMA20Monthly Average Dollar Volume: >= 1,000,000

Ticker

Name

Market Cap$

BIIB

Biogen Inc

26.91B

MRNA

Moderna Inc

21.65B

ILMN

Illumina Inc

20.18B

INCY

Incyte Corp

19.29B

EXEL

Exelixis Inc

11.08B

CRSP

CRISPR Therapeutics AG

5.56B

Stocks for short term gans

Intellectia · 19 candidates

Market Cap: >= 2.00BRsi Category: moderate, overboughtRelative Vol: >= 2Moving Average Relationship: PriceAboveMA20Week Price Change Pct: >= $10.00

Ticker

Name

Market Cap$

LBTYB

Liberty Global Ltd

6.07B

PAHC

Phibro Animal Health Corp

2.15B

ALGT

Allegiant Travel Co

2.10B

NVST

Envista Holdings Corp

4.77B

XPO

XPO Inc

23.85B

RRX

Regal Rexnord Corp

14.06B

NASDAQ100 stock with fairly or undervalue

Intellectia · 10 candidates

Analyst Consensus: Strong Buy, Moderate Buy, HoldPe Ttm: 8 - 22P/B Ratio: <= 4.00Is Index Component: NDXEv Ebitda: <= 15

Ticker

Name

Market Cap$

FANG

Diamondback Energy Inc

44.13B

PDD

PDD Holdings Inc

152.56B

PYPL

PayPal Holdings Inc

53.15B

BIIB

Biogen Inc

25.32B

TMUS

T-Mobile US Inc

211.11B

CTSH

Cognizant Technology Solutions Corp

41.28B

list of biotech stock

Intellectia · 11 candidates

Market Cap: >= 1000.00MThemes: BiotechBeta: LowRiskWeekly Average Turnover: >= 1,000,000Is Optionable: True

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

show me onlybiostock

Intellectia · 19 candidates

Themes: BiotechWeekly Average Turnover: >= 1,000,000

Ticker

Name

Market Cap$

AMGN

Amgen Inc

185.02B

GILD

Gilead Sciences Inc

160.18B

VRTX

Vertex Pharmaceuticals Inc

117.00B

REGN

Regeneron Pharmaceuticals Inc

78.75B

BNTX

Biontech SE

29.61B

BIIB

Biogen Inc

25.32B

Whales Holding BIIB

Mubadala Investment Company PJSC

Capula Management Ltd

PRIMECAP Management Company

MAPFRE Asset Management

Portolan Capital Management, LLC

Brevan Howard Capital Management LP

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biogen Inc (BIIB) stock price today?

The current price of BIIB is 193.45 USD — it has increased 1.08

What is Biogen Inc (BIIB)'s business?

What is the price predicton of BIIB Stock?

Wall Street analysts forecast BIIB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIIB is204.45 USD with a low forecast of 143.00 USD and a high forecast of 246.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Biogen Inc (BIIB)'s revenue for the last quarter?

Biogen Inc revenue for the last quarter amounts to 2.48B USD, increased 1.93

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

Biogen Inc. EPS for the last quarter amounts to 2.15 USD, increased 31.10

How many employees does Biogen Inc (BIIB). have?

Biogen Inc (BIIB) has 7500 emplpoyees as of May 10 2026.

What is Biogen Inc (BIIB) market cap?

Today BIIB has the market capitalization of 28.56B USD.

BIIB Overview

BIIB Overview

Events Timeline

News

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Related Community Screener

Whales Holding BIIB

Trading Trends

People Also Watch

Frequently Asked Questions

What is Biogen Inc (BIIB) stock price today?

What is Biogen Inc (BIIB)'s business?

What is the price predicton of BIIB Stock?

What is Biogen Inc (BIIB)'s revenue for the last quarter?

What is Biogen Inc (BIIB)'s earnings per share (EPS) for the last quarter?

How many employees does Biogen Inc (BIIB). have?

What is Biogen Inc (BIIB) market cap?